Arecor enhances IP coverage for AT278 and Oral Delivery Technology

AT278 IP

Arecor has strengthened its patent protection for its lead programme, AT278, the only ultra-concentrated and ultra-rapid acting insulin in development with the potential to enable longer-wear for existing automated insulin delivery (AID) systems and their future miniaturisation. A US patent has been granted to protect key formulations and uses of AT278. In addition, another patent with respect to AT278 intellectual property has been approved for grant by the European Patent Office, providing further patent protection in Europe.

Oral peptide delivery IP

Arecor has also filed a patent application with the European Patent office, claiming novel compositions to improve the oral bioavailability of complex peptides. Novel peptide therapeutics are proving to be highly effective to treat chronic conditions such as obesity, diabetes and other cardiometabolic diseases, and there is growing evidence that oral delivery improves patient compliance and adherence.

Poor oral bioavailability remains a major barrier to developing convenient oral peptide therapies. Arecor is addressing this challenge through novel therapeutic formulations designed to improve the oral bioavailability of peptides. The new patent application protects the key formulation design space discovered in initial investigations with additional patent applications expected to follow as R&D progresses.

Dr Jan Jezek, CSO of Arecor said:

“As an innovative company developing novel therapies and platforms, protecting our IP is essential to our business. We are continuously updating our IP protection to secure its value and we are pleased to have received additional patent protection in Europe and the US for our ultra-concentrated ultra-rapid acting insulin, AT278. We have also filed our first patent application in the oral peptide delivery space, which is an important moment for us, with more to come as our R&D programme progresses.” 

The new patents add to a robust global intellectual property portfolio of the Company protecting AT278 and the Arestat® technology, and follow a number of additional patents already granted in major territories.